Emicizumab Antibody

SKU: orb1905844

Description

Emicizumab (ACE 910) is a bispecific antibody that substitutes for activated factor VIII by bridging factors IXa and Xa. It is applied in hemophilia A research, including in vitro coagulation studies and in vivo models for prophylactic and therapeutic effect evaluation.

Research Area

Metabolism Research

Images & Validation

−

Key Properties

−

CAS Number	1610943-06-0
MW	145.14 kDa
Purity	95.9% (SEC-HPLC)
Target	Factor VIII,Others

Bioactivity

−

In Vivo	Emicizumab (1.5-10 mg/kg; i.v.; 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia type A bleeding model with an FVIII equivalent of 9 U/dL. Emicizumab (3 mg/kg; intravenously) provides additional hemostatic activity when combined with low-dose FVIII (10 U/dL). Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

RO 5534262, RO5534262, RO-5534262, Emicizumab, ACE 910, ACE910, ACE-910

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

Factor VIII,Others

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols